

VOLUME 41

NUMBER 5

AUGUST 3, 1987

# LIFE SCIENCES

The International Medium  
for Rapid Publication of Communications  
in the Life Sciences

HEALTH SCIENCES LIBRARY

University of Wisconsin

1305 Linden Dr., Madison, Wis. 53706

JUL 03 1987



**PERGAMON PRESS**

NEW YORK • OXFORD • BEIJING • FRANKFURT  
SÃO PAULO • SYDNEY • TOKYO • TORONTO

PAR1039

IPR of U.S. Patent No. 8,772,306

Page 1 of 8

(ISSN 0024-3205)

Founder: B.B. Brodie

Executive Editor: R. Bressler, M.D.

## ASSOCIATE EDITORS

K. Brendel, Ph.D.	D.L. Kreulen, Ph.D.	D.H. Russell, Ph.D.
T.F. Burks, Ph.D.	T.J. Lindell, Ph.D.	I.G. Sipes, Ph.D.
D.G. Johnson, M.D.		H.I. Yamamura, Ph.D.

Journal Production Editor: Wayne Blankenship  
Assistant Production Editor: Diann Sheldon Kimsey

Editorial Office: Department of Pharmacology, College of Medicine,  
University of Arizona, Tucson, AZ 85724, USA

## EDITORIAL ADVISORY BOARD

Julius Axelrod, USA	Laurel A. Fisher, USA	Horace H. Loh, USA
Floyd E. Bloom, USA	William W. Fleming, USA	Elias Meezan, USA
Marvin R. Brown, USA	Ray W. Fuller, USA	Joseph Meites, USA
Michael J. Brownstein, USA	Jay Gandolfi, USA	Herbert Y. Meltzer, USA
David R. Burt, USA	Dwight C. German, USA	Kenneth E. Moore, USA
Kevin J. Catt, USA	James R. Gillette, USA	Sheldon D. Murphy, USA
Steven R. Childers, USA	Gregory Gregoriadis, UK	Richard W. Olsen, USA
Arthur K. Cho, USA	Alessandro Guidotti, USA	Bert W. O'Malley, USA
Marlene L. Cohen, USA	Mark R. Haussler, USA	Gavril W. Pasternak, USA
Erminio Costa, USA	Jacob M. Hiller, USA	Frank Porreca, USA
Alan Cowan, USA	John W. Holaday, USA	Peter W. Ramwell, USA
Brian M. Cox, USA	Jerry B. Hook, USA	Russel J. Reiter, USA
Joseph T. Coyle, USA	Akira Horita, USA	William R. Roeske, USA
Ian Creese, USA	Victor J. Hruby, USA	Andrew V. Schally, USA
Pedro Cuatrecasas, USA	Leslie L. Iversen, UK	Thomas L. Smith, USA
John W. Daly, USA	Donald J. Jenden, USA	Solomon H. Snyder, USA
Thomas P. Davis, USA	Arnold M. Katz, USA	Sydney Spector, USA
Richard A. Deitrich, USA	Peter T. Kissinger, USA	David U'Prichard, USA
Andre Dray, UK	David M. Kochhar, USA	John R. Vane, UK
Sam J. Enna, USA	Irwin J. Kopin, USA	Elliot S. Vesell, USA
John N. Fain, USA	William E.M. Lands, USA	Eddie Wei, USA
John D. Fernstrom, USA	Robert J. Lefkowitz, USA	Richard J. Wurtman, USA

*Publishing, Subscription and Advertising Offices:* Pergamon Journals Inc., Fairview Park, Elmsford, New York 10523, USA, and Pergamon Journals Ltd., Headington Hill Hall, Oxford OX3 0BW, England.

*Published Weekly* (2 volumes of 26 numbers each per annum): *Annual institutional subscription rate* (1987) DM2860.00; *Two-year institutional subscription rate* (1987/88): DM5434.00; *Personal subscription rate* for those whose library subscribes at the regular rate (1987): DM357.00. Prices are subject to change without notice. Notify 8 weeks in advance of address change with a copy of the subscription mailing label. *Microforms subscriptions:* Information available upon request.

Copyright © 1987 Pergamon Journals Ltd. • Printed in the USA.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

*Photocopying information for users in the U.S.A.:* The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of \$3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970.

*Permission for other use:* The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. Please contact the Subsidiary Rights Manager, Publishing Services Dept. at either Pergamon Journals Ltd. or Pergamon Journals Inc.

*The Item-Fee Code for this publication is:* 0024-3205/87 \$3.00 + .00

Second class postage paid at Elmsford, N.Y. and additional offices.

Postmaster: Send address changes to: Pergamon Journals Inc., Fairview Park, Elmsford, NY 10523.

3'-5' CYCLIC-GUANOSINE MONOPHOSPHATE INCREASE IN RAT BRAIN HIPPOCAMPUS AFTER  
GAMMA-HYDROXYBUTYRATE ADMINISTRATION. PREVENTION BY VALPROATE AND NALOXONE.

Philippe Vayer, Serge Gobaille, Paul Mandel and Michel Maitre

Centre de Neurochimie du CNRS and INSERM U44, 5 rue Blaise Pascal,  
67084 STRASBOURG Cedex.

(Received in final form May 21, 1987)

Summary

An increase (123%) of cyclic GMP (cGMP) was observed in the hippocampus of the rat killed by microwave irradiation 45 min after administration of 500 mg/kg  $\gamma$ -hydroxybutyrate (GHB) IP. This increase is time and dose dependent. No modification in cyclic nucleotide content was observed in striatum and in cerebellum. As the role of GHB has been implicated in neurotransmission, the fact that this compound increases cyclic GMP accumulation in hippocampus in vivo may represent a mechanism by which the actions of GHB are mediated at the cellular level. Valproate (400 mg/kg) or naloxone (10 mg/kg) pretreatment completely abolish the cGMP increase due to GHB. A GABAergic and/or opiate phenomenon may be involved in the mechanism of GHB induced increase of cGMP.

An increase of adenosine 3'-5' cyclic-adenosine-monophosphate (cAMP) or of 3'-5' cyclic-guanosine-monophosphate (cGMP) or both have been observed after administration of several convulsant drugs and agents in experimental animals (1,2). Moreover, agents that lead to behavioral excitation tend to increase cGMP levels whereas those that depress motor activity decrease its levels (2). Interestingly,  $\gamma$ -hydroxybutyrate (GHB) which occurs naturally in the brains of several mammalian species (3) including man (4), induces when administered to animals a state of behavioral sedation often called sleep or anaesthesia (5). In addition, GHB induces hypersynchronism in the electroencephalographic pattern in rat, rabbit and man (6,7,8). These effects have been described as epileptoid E.E.G. seizures which can be antagonized by anti-petit mal drugs. Besides these effects, GHB is a good candidate for a role in neurotransmission or neuromodulation (9). The cyclic nucleotides, involved in the cellular action of numerous neurotransmitters, can also mediate the neuroregulatory effects of GHB in mammalian brain. The aim of this paper is to investigate the effect of exogenous GHB on the level of cyclic nucleotides in three regions of the rat brain: hippocampus, which is considered as the burst generator for several acute epilepsy models (10,11), cerebellum, where cyclic nucleotides have been extensively studied (12,13,14), and striatum where GHB interacts with the dopaminergic system (8-15).

Materials and Methods

Male adult Wistar rats weighing about 300 g were used in all studies. The animals were injected IP with GHB (sodium salt) and/or with the other test substances (sodium valproate, or naloxone hydrochloride). The rats were sacrificed after appropriate times by exposing the head to focused microwave irradiation (7.5 kW, 1.6 sec. exposure) which prevents post-mortem changes in cyclic nucleotide levels (16). The dissected brain regions were kept in liquid

0024-3205/87 \$3.00 + .00

Copyright (c) 1987 Pergamon Journals Ltd.

PAR1039

IPR of U.S. Patent No. 8,772,306

Page 3 of 8

nitrogen, weighed frozen and homogenized in 10 vols 1M ice cold perchloric acid. Protein was removed by centrifugation at 20,000 g for 25 min. The supernatants were neutralized with 3M  $K_2CO_3$  and cyclic nucleotide contents were determined with the cAMP kit and the cGMP R.I.A. kit from Amersham (Radiochemical Center). Protein contents of the different pellets were measured by the Lowry method (17) after solubilization in 2N NaOH.

### Results

#### Cyclic nucleotides as a function of time after GHB administration

Cyclic nucleotide levels were measured every 10 min during 120 min after injection at time zero of 500 mg/kg GHB. No significant changes were found for cGMP and cAMP in the cerebellum or in the striatum. (cGMP: cerebellum ( $3.02 \pm 0.48$  pmole/mg protein), striatum ( $0.25 \pm 0.06$  pmole/mg protein); cAMP: cerebellum ( $6.29 \pm 0.53$  pmole/mg protein), striatum ( $3.14 \pm 0.56$  pmole/mg protein). In the hippocampus, the level of cGMP ( $0.28 \pm 0.05$  pmole/mg protein) increases with time. The rise of cGMP was first noted 20 min after injection of GHB, with a maximum at 30-50 min ( $0.63 \pm 0.04$  pmole/mg protein). After 110 min, the basal level of cGMP is restored (Fig. 1). For cAMP, no significant changes were found ( $3.57 \pm 0.96$  pmole/mg protein).

#### Effect of various concentrations of GHB on cGMP levels in hippocampus

200 mg/kg to 700 mg/kg GHB were administered IP to rats which were killed after 45 min by microwave irradiation. cGMP levels were determined in the dissected hippocampus. Fig. 2 shows that the maximum increase in cGMP occurs for 400 - 500 mg/kg. Higher doses induced less accumulation of cGMP.

#### Effect of valproate on the cGMP increase induced by GHB in hippocampus

The animals were injected either with valproate (400 mg/kg IP) or with GHB (400 mg/kg IP) or pretreated with valproate (400 mg/kg IP) 15 min before GHB injection (400 mg/kg IP). In all cases, 45 min after the last injection, the animals were killed as described above and cGMP was determined in the hippocampus. Fig. 3 shows that valproate does not modify cGMP content, but GHB increases cGMP in hippocampus by about 140% compared to controls injected with saline. However, pretreatment with valproate completely abolishes the GHB effect on cGMP levels (Fig. 3). Under these conditions, no modifications of cGMP levels are observed compared to controls injected with saline or with valproate alone.

#### Effect of naloxone on the cGMP increase induced by GHB

For these experiments, the same protocol as described for the experiment with valproate was adopted, but this latter compound was replaced by administration of naloxone (10 mg/kg IP). As indicated by SNEAD et al. (19) naloxone completely blocked behavioral changes induced by administration of GHB. In particular, no catalepsy was observed in animals receiving both naloxone and GHB. Pretreatment with naloxone blocks the GHB effect on cGMP levels (Fig. 4).

### Discussion

This work demonstrates the increase of cGMP accumulation induced by GHB in rat brain hippocampus. The control values of cGMP are identical to those previously described for hippocampus of rats sacrificed by microwave irradiation (18). No changes were found in the other regions studied either for cGMP or for cAMP levels. GHB caused a time and dose dependent accumulation of




FIG. 1

cGMP levels in hippocampus as a function of time after GHB administration (500 mg/kg IP). Each point represents the mean of 3 different determinations  $\pm$  S.E.M.. The cGMP levels between 20 and 100 min are significantly different from the control with  $p < 0.05$  (Student's t test).




FIG. 2

Effect of various GHB doses on cGMP levels in hippocampus. The rats were killed 45 min after GHB injection IP. Each point represents the mean of 3 different determinations  $\pm$  S.E.M. The cGMP levels between 400 and 600 mg/kg are significantly different from the control with  $p < 0.05$  (Student's t test).

PAR1039

IPR of U.S. Patent No. 8,772,306

Page 5 of 8

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.